skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

Clinical Pharmacology & Therapeutics, 2020-08 [Peer Reviewed Journal]

2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com ;DOI: 10.1002/cpt.1844

Digital Resources/Online E-Resources

Citations Cited by
  • Title:
    Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
  • Author: Yin‐Xiao Du ; Xiao‐Ping Chen
  • Is Part Of: Clinical Pharmacology & Therapeutics, 2020-08
  • Description: An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID‐2019. In addition to the recommended antiviral drugs, such as interferon‐ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA‐dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug–drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID‐2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.
  • Publisher: Hoboken: John Wiley & Sons, Inc
  • Language: English
  • Identifier: DOI: 10.1002/cpt.1844
  • Source: Coronavirus Research Database

Searching Remote Databases, Please Wait